Casgevy, the First CRISPR Medicine, Expands to Children as Young as 2
Updated: 11 hours ago
In July 2026, the FDA expanded the approval of Casgevy (exagamglogene autotemcel) to children aged 2 and older with sickle cell disease or transfusion-dependent beta-thalassemia. Casgevy, developed by Vertex Pharmaceuticals with CRISPR Therapeutics, made history in December 2023 as the first CRISPR-based medicine approved in the U.S. Until now, it was available only to patients aged 12 and up.
The expansion followed strong Phase 1 results in children aged 5 to 11. For the youngest group, ages 2 to 4, the FDA relied on what it called "extrapolation from product characteristics and the available clinical evidence," rather than direct trial data in that age group. That detail makes this approval notable well beyond these two diseases.
Two diseases, one molecule
Sickle cell disease and beta-thalassemia are both disorders of hemoglobin, the protein that carries oxygen in red blood cells.
In sickle cell disease, a single-letter mutation makes hemoglobin clump together. Red cells bend into rigid sickle shapes that block blood vessels, causing severe pain crises, organ damage, stroke, and shortened life expectancy.
In beta-thalassemia, mutations reduce or eliminate production of the beta chain of adult hemoglobin. People with the transfusion-dependent form need blood transfusions every few weeks for life, and iron overload from those transfusions causes its own damage.
For many patients, damage starts early in childhood. That's why treating younger children has been a long-standing goal.
How Casgevy works: reactivating fetal hemoglobin
Casgevy doesn't fix the faulty adult hemoglobin gene. It takes a clever detour.
Before birth, we make fetal hemoglobin, a version that doesn't sickle and carries oxygen very well. Shortly after birth, the body switches it off and turns on adult hemoglobin. A gene called BCL11A is one of the main switches that shuts fetal hemoglobin down.
Nature again showed the way. Some people naturally keep making fetal hemoglobin as adults. When they also inherit sickle cell or thalassemia mutations, their disease is often much milder.
Casgevy uses CRISPR-Cas9 to cut and disrupt a small control region, an enhancer, that switches on BCL11A specifically in red blood cell precursors. With that switch disabled, the cells go back to making fetal hemoglobin. Casgevy does not correct the disease-causing mutation. Instead, it reactivates gamma-globin genes the patient already carries, and the resulting fetal hemoglobin compensates for the defective adult form.
The treatment process
Casgevy is an ex vivo therapy, and the process is demanding:
Doctors collect the patient's own blood stem cells.
In a specialized facility, the cells are edited with CRISPR.
The patient receives high-dose busulfan chemotherapy to clear the bone marrow.
The edited cells are infused back, where they settle in and begin producing red cells rich in fetal hemoglobin.
The whole journey can take many months, including a long hospital stay while the new marrow grows in. For adults, it's a major undertaking. For toddlers, it requires careful planning by specialized pediatric teams.
Why extrapolation is the big story
Running trials in very young children is hard. There are fewer patients, the procedures are intensive, and families understandably hesitate. If every approval required separate trial data for each age group, toddlers would wait years longer than adults for the same therapy.
The FDA's decision rests on a scientific argument. The product and its mechanism are the same across ages. The edit targets the same switch in the same type of cell, and data from older children showed consistent results. On that basis, the agency judged the benefit could reasonably be expected to carry over.
This fits a wider pattern this year. Regulators have been more willing to draw on all the available evidence, including platform knowledge and data from related populations, especially in serious diseases where waiting has its own costs.
The concerns that remain
Conditioning is the hardest part. Busulfan is toxic. Its known risks include infertility, which is a significant consideration for young children whose families must weigh it now on their behalf. Gentler conditioning approaches are being studied, and they would make therapies like Casgevy much easier to recommend.
Access and cost. Casgevy is one of the most expensive medicines ever approved, and it can only be given at qualified treatment centers. Much of the global burden of sickle cell disease is in sub-Saharan Africa and India, where access to this kind of therapy is very limited.
Long-term follow-up. For a child treated at age 2, the relevant question is how the edited cells perform over 70 or 80 years. Ongoing monitoring will keep answering that question over time.
The bottom line
By opening Casgevy to children as young as 2, the FDA has made it possible to treat sickle cell disease and beta-thalassemia before years of damage build up. The decision to extrapolate to the youngest patients is as important as the approval itself. It signals that proven gene-editing therapies may not have to restart the clock for every new age group.
Keep exploring with Gene Tech Times
Free guide: subscribe to the Gene Tech Times Briefing on our homepage and get Every FDA-Approved Gene Therapy at a Glance in your inbox.
Watch: 30-second gene therapy Shorts on Gene Tech Times Academy.
Read: The Cheat Codes of Our Genes, real stories of mutations that make some people immune to disease.
New to gene therapy? Start with The Life-Changing Power of Gene Therapy.
— T.N., Gene Tech Times
Comments